Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [18F]-2-fluoro-2-deoxy-D-mannose: A new tracer for cancer detection

Hiroshi Fukuda, Taiju Matsuzawa, Yoshinao Abe, Satoshi Endo, Kenji Yamada, Kazuo Kubota, Jun Hatazawa, Tachio Sato, Masatoshi Ito, Toshihiro Takahashi, Ren Iwata, Tatsuo Ido

Research output: Contribution to journalArticlepeer-review

63 Citations (Scopus)

Abstract

18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and 18F-2-fluoro-2-deoxy-D-mannose (18F-FDM) were tested as tumor diagnostic agents in a transplantable rat tumor and rabbit tumors. Tissue distribution studies in rats showed high tumor uptakes of both radiopharmaceuticals. The tumor uptake reached 2.65±0.61% dose 18F-FDG/g and 2.65±0.81% dose 18F-FDM/g at 60 min and remained relatively constant until 120 min. Blood clearance of both 18F-FDG and 28F-FDM was very rapid and tumor-to-blood ratios reached 22.1 and 29.4 at 60 min, respectively. Tumor-to-tissue ratios of both radiopharmaceuticals were very high in most organs, especially in the liver, kidney, and pancreas. Positron emission tomography (PET) of rabbit tumor with 18F-FDM clearly delineated the main tumor, central necrosis, and lymph node metastases. These data suggested that 18F-FDM which is a by-product of 18F-FDG synthesis, was also an excellent cancer diagnostic agent as well as 18F-FDG. This is not only a new feature of 18F-FDM, but also an economical improvement on cancer diagnosis by PET.

Original languageEnglish
Pages (from-to)294-297
Number of pages4
JournalEuropean Journal of Nuclear Medicine
Volume7
Issue number7
DOIs
Publication statusPublished - 1982 Jul 1

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [<sup>18</sup>F]-2-fluoro-2-deoxy-D-mannose: A new tracer for cancer detection'. Together they form a unique fingerprint.

Cite this